Hims & Hers Health, Inc. (HIMS) Q3 2024 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Bill Newby - Head, IR Andrew Dudum - Co-Founder and CEO Yemi Okupe - CFO Patrick Carroll - Chief Medical Officer Conference Call Participants Allen Lutz - Bank of America Maria Ripps - Canaccord Daniel Grosslight - Citi Eric Percher - Nephron Research Ryan MacDonald - Needham Aaron Kessler - Seaport Research Jonna Kim - TD Cowen Jailendra Singh - Truist Securities Operator Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today.
Markets Temper Enthusiasm Ahead of Election Day
We don't expect any sudden movements in the stock market until Wednesday morning the earliest.
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.
HIMS Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the third quarter.
Could This Magnificent Pharma Stock 10x in the Next 5 Years?
Disrupting pharmacies is just the start for Hims & Hers.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers Health, Inc. (HIMS) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $21.52, marking a +0.65% move from the previous day.
Hims & Hers Stock Dropped: Here's What You Need to Know
The GLP-1 drama continues at Hims & Hers.
Hims & Hers Health Tops Growth 50 List As FDA OKs Cheaper Weight-Loss Drug
Hims stock is near its all time high and a buy point of 25.74.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
